Breaking News Instant updates and real-time market news.

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55

American Society of Human Genetics to hold a conference

ASHG Conference 2018 will be held in San Diego, CA on October 16-20.

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

A Agilent
$64.47

-1.28 (-1.95%)

09/17/18
GSCO
09/17/18
DOWNGRADE
GSCO
Neutral
Thermo Fisher downgraded to Neutral from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly downgraded Thermo Fisher (TMO) to Neutral from Conviction Buy with an unchanged price target of $250. The analyst coupled the downgrade with an upgrade of Agilent Technologies (A) to Conviction Buy from Buy. The analyst believes his thesis on Thermo Fisher, centering around deal-driven accelerating growth and margin expansion, is more appropriately reflected in the current valuation. Further, the company faces a difficult set of comps starting in Q4 of this year, Donnelly tells investors in a research note. The analyst remains positive on Thermo Fisher's fundamentals, but prefers the set-up for Agilent at current valuation levels.
06/08/18
BARD
06/08/18
NO CHANGE
Target $77
BARD
Outperform
Agilent recent weakness a buying opportunity, says Baird
Baird analyst Catherine Ramsey Schulte attended Agilent's analyst day and said her positive outlook on the company remains unchanged. She continues to expect strong core growth and margin expansion to help drive above market performance over the next several years. Schulte said she would use recent weakness as a buying opportunity and reiterated her Outperform rating and $77 price target on Agilent shares.
06/28/18
JPMS
06/28/18
DOWNGRADE
Target $105
JPMS
Underweight
JPMorgan downgrades Varian to Underweight following period of restriction
JPMorgan analyst Tycho Peterson downgraded Varian Medical Systems (VAR) to Underweight from Neutral following a period of restriction. Persistent order growth volatility, a "sluggish" end market and in the near-term and risk from the U.S.-China trade war weigh on the analyst's longer-term outlook for the stock. Varian has a dominant franchise but a mature industry and premium valuation are hard to overlook, Peterson tells investors in a research note. The analyst sees better risk/rewards in other parts of his coverage universe, including tool names Agilent (A), Danaher (DHR) and Thermo Fisher (TMO).
09/17/18
GSCO
09/17/18
UPGRADE
Target $82
GSCO
Conviction Buy
Agilent upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly added Agilent Technologies (A) to his firm's Conviction List and keeps a Buy rating on the shares. The analyst upped his price target for the stock to $82 from $77. Donnelly names Agilent his top pick in Life Science Tools ahead of Q3 earnings season. Agilent provides a "a rare Tools opportunity" to own an "accelerating growth story at a reasonable valuation," Donnelly tells investors in a research note. Further, the analyst sees "untapped capital allocation upside" that could potentially be unlocked by the new CFO.
AGLE Aeglea BioTherapeutics
$9.32

-0.58 (-5.86%)

06/14/18
BMOC
06/14/18
INITIATION
Target $21
BMOC
Outperform
Aeglea BioTherapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Matthew Luchini initiated Aeglea BioTherapeutics with an Outperform rating and a price target of $21. The analyst states that its lead drug, pegzilarginase, may "transform" the Arginase I Deficiency treatment, with the results from the Phase 1/2 trial for two patients showing improvement in clinically relevant endpoints. Luchini anticipates Q3 results to confirm the data, leading to the initiation of a phase 3 trial next year and a potential approval in 2021. The analyst adds that expansion into oncology and other preclinical studies for pegzilarginase offer further upside.
04/24/18
04/24/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. First Data (FDC) initiated with a Buy at Mizuho. 2. Allergan (AGN) resumed with a Buy at Citi. 3. Alder Biopharmaceuticals (ALDR) initiated with a Neutral at Goldman Sachs. 4. ConvergeOne (CVON) initiated with an Outperform at Cowen. 5. Aeglea BioTherapeutics (AGLE) initiated with an Outperform at Evercore ISI. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/04/18
09/04/18
DOWNGRADE
Target $10

Market Perform
Aeglea downgraded to Market Perform on potential development risk at Wells Fargo
As previously reported, Wells Fargo analyst Aeglea BioTherapeutics to Market Perform from Outperform on potential increased development risk following review of updated interim phase 1/2 data for pegzilarginase in Arginase 1 Deficiency. The analyst also lowered his price target on the shares to $10 from $24.
09/04/18
WELS
09/04/18
DOWNGRADE
WELS
Market Perform
Aeglea BioTherapeutics downgraded to Market Perform at Wells Fargo
ALXN Alexion
$125.96

-0.63 (-0.50%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
09/27/18
NOMU
09/27/18
NO CHANGE
Target $161
NOMU
Buy
Alexion acquisition bodes well for Argenx, says Nomura Instinet
Nomura Instinet analyst Christopher Marai believes Alexion Pharmaceuticals' (ALXN) acquisition of Syntimmune highlights potential demand for FcRn therapies by acquirers and bodes well for Argenx (ARGX). The analyst keeps a Buy rating on Argenx with a $161 price target.
09/28/18
LEHM
09/28/18
NO CHANGE
Target $175
LEHM
Overweight
Alexion price target raised to $175 from $165 at Barclays
Barclays analyst Geoff Meacham raised his price target for Alexion Pharmaceuticals to $175 saying this week's positive Phase 3 of Soliris data in neuromyelitis optica spectrum disorder "was a positive surprise for many and is the latest in a string of 'wins' for the company." The analyst thinks Alexion remains one of the more compelling names in biotech and he keeps an Overweight rating on the shares.
10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
RHHBY Roche
$0.00

(0.00%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
BMRN BioMarin
$103.31

-0.52 (-0.50%)

10/01/18
CANT
10/01/18
INITIATION
Target $126
CANT
Overweight
BioMarin initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started BioMarin with an Overweight rating and $126 price target.
10/16/18
JEFF
10/16/18
NO CHANGE
Target $125
JEFF
Buy
BioMarin price target raised to $125 from $118 at Jefferies
Jefferies analyst Eun Yang raised her price target for BioMarin to $125 saying that with multiple clinical catalysts in 2019-2020 supporting potential regulatory approval of three new products, she expects the stock to move higher. If pivotal trials for the three new products, valrox in hemophilia A gene therapy, vosoritide in achondroplasia, and BMN-250 in Sanfilippo B syndrome, are successful, the analyst sees a fair value for BioMarin at $140 per share. The stock's current risk/reward is favorable, particularly with currently marketed products providing a $90 per share "valuation floor," Yang tells investors in a research note. She keeps a Buy rating on BioMarin.
09/06/18
PIPR
09/06/18
NO CHANGE
Target $120
PIPR
Overweight
Piper 'incrementally positive' on BioMarin after Valrox filing plans
Piper Jaffray analyst Christopher Raymond is "incrementally positive" on BioMarin shares after the company disclosed at a conference today that it plans to file for accelerated approval of Valrox, the company's hemophilia gene therapy, in the second half of 2019. The analyst notes this is a full year earlier than he currently models. Pulling Valrox forward by one year adds approximately $10 per share to the stock, Raymond tells investors in a research note. He keeps an Overweight rating on BioMarin with a $120 price target. The stock in early trading is up 2c to $96.62.
BIO Bio-Rad
$280.96

-3.23 (-1.14%)

09/20/18
09/20/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Westport (WPRT) initiated with a Buy at H.C. Wainwright. 2. Legacy Reserves (LGCY) initiated with a Neutral at Seaport Global. 3. Tandem Diabetes (TNDM) initiated with a Buy at Craig-Hallum. 4. Bio-Rad (BIO) initiated with an Equal Weight at Morgan Stanley. 5. Brookfield (BAM) initiated with an Outperform at BMO Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
MSCO
09/20/18
INITIATION
Target $335
MSCO
Equal Weight
Bio-Rad initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw initiated Bio-Rad with an Equal Weight rating and $335 price target, stating that its organic growth acceleration, margin expansion and $1.5B increase in the value of its 30% stake in German bioprocess/lab products and instruments maker Sartorius add up to a "great story," but a stock that is "not cheap." He expects EPS to track 5%-10% above consensus by 2020, but still struggles to find upside given the stock's current levels, Beuchaw tells investors.
09/24/18
JEFF
09/24/18
NO CHANGE
Target $420
JEFF
Buy
Jefferies boosts Bio-Rad target to $420, adds to Franchise Picks List
Jefferies analyst Brandon Couillard raised his price target for Bio-Rad Laboratories to $420 and added the shares to his firm's Franchise Picks List. The analyst sees "substantial hidden value" in Bio-Rad's droplet digital PCR franchise that he believes is underappreciated by investors. ddPCR is a disruptive technology that can grow at 20%-plus annually, capable of driving a sustained organic growth acceleration for the company thru 2021, Couillard tells investors in a research note. Further, he believes base Bio-Rad business trades at only 6.3 times estimated 2020 EBITDA, or a 60% discount to peers. The analyst keeps a Buy rating on the shares.
10/17/18
GSCO
10/17/18
INITIATION
Target $350
GSCO
Buy
Bio-Rad initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Patrick Donnelly started Bio-Rad Laboratories with a Buy rating and $350 price target. The analyst sees above-average earnings growth for the company and thinks its margin expansion story is in the early stages.
MSFT Microsoft
$108.55

0.01 (0.01%)

10/12/18
10/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Microsoft (MSFT) upgraded to Outperform from Neutral at Macquarie with analyst Sarah Hindlian saying she is taking advantage of the pullback in shares. 2. Netflix (NFLX) upgraded to Buy from Neutral at Citi with analyst Mark May saying the valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy. 3. Square (SQ) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying the recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company." 4. Snap (SNAP) upgraded to Buy from Hold at Pivotal Research with analyst Brian Wieser saying despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." 5. Costco (COST) upgraded to Buy from Neutral at Northcoast. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/18
10/12/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. MICROSOFT UPGRADED TO OUTPERFORM AFTER PULLBACK: Macquarie analyst Sarah Hindlian upgraded Microsoft (MSFT) to Outperform from Neutral and raised her price target on the shares to $121, saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work. CITI UPGRADES NETFLIX TO BUY: Citi analyst Mark May upgraded Netflix (NFLX) to Buy from Neutral with an unchanged price target of $375. The valuation, following this week's selloff, has reached a level that warrants an "opportunistic" upgrade to Buy, May said. Netflix has a highly recurring subscription-based revenue business that delivers "significant value" to consumers, and its management team has a strong track record of execution, the analyst contended. Further, he believes the company's fundamentals remain strong and that is has opportunity to continue growing international subscribers. SQUARE UPGRADED TO BUY AFTER PULLBACK: Canaccord Genuity analyst Michael Graham upgraded Square (SQ) to Buy from Hold and raised his price target for the shares to $90 from $60. The recent pullback in the shares creates a long-term opportunity in a "truly disruptive and well-run company," Graham said. He believes the departure of CFO Sarah Friar is more about going to a promising company as CEO rather than walking away from a risk. PIVOTAL UPGRADES SNAP TO BUY: Pivotal Research analyst Brian Wieser upgraded Snap (SNAP) to Buy from Hold while lowering his price target for the shares to $8 from $9. The analyst said that despite declining usage and liquidity, the data he looks at is showing a "widening user base, although one which is collectively reducing its time on the platform." It is not too late for management to find ways to reverse recent usage trends and generally improve monetization regardless of those usage trends, Wieser added. Further, the analyst believes Snap could become an attractive candidate to go private with the stock's price at current levels. JPMORGAN DOWNGRADES ESTEE LAUDER TO NEUTRAL: JPMorgan analyst Andrea Teixeira downgraded Estee Lauder (EL) to Neutral and lowered her price target for the shares to $138 from $154. There may be a deceleration in the travel retail channel ahead now that Chinese customs agents are implementing tighter controls at the border, according to local source, Teixeira noted. Further, she believes the de-rating in luxury peers related to the group's "outsized exposure" to Chinese consumers will likely put a cap on Estee Lauder's valuation as well. The analyst also sees less opportunity for earnings beats on margins in the near term given tariff costs.
10/18/18
WEDB
10/18/18
INITIATION
WEDB
Outperform
Microsoft initiated with an Outperform at Wedbush
10/19/18
WEDB
10/19/18
INITIATION
Target $140
WEDB
Outperform
Microsoft initiated with an Outperform at Wedbush
Wedbush analyst Daniel Ives initiated Microsoft with an Outperform rating and $140 price target, telling investors in a research note that he believes Microsoft is on track to become the next member of the trillion dollar market cap club. He says the shift to cloud is a major secular trend that is significantly benefiting Microsoft in the field as a key tailwind and should continue its momentum heading into FY19, and adds that the cloud story "is showing no signs of abating."
ILMN Illumina
$313.31

-7.98 (-2.48%)

10/09/18
UBSW
10/09/18
NO CHANGE
UBSW
UBS initiates coverage of Life Sciences and Diagnostics Tools sector
UBS analyst Daniel Brennan initiated coverage of the Life Sciences and Diagnostics Tools sector. He said demand is accelerating across his universe but valuations are extended. He expects strong fundamentals to continue into 2019 but he said selectivity is the key. In the group, his Buy ratings include Exact Sciences (EXAS), Iqvia (IQV), NanoString (NSTG), Syneos Health (SYNH) and Thermo Fisher (TMO).
10/09/18
UBSW
10/09/18
INITIATION
Target $340
UBSW
Neutral
Illumina initiated with a Neutral at UBS
UBS analyst Daniel Brennan initiated Illumina with a Neutral rating and $340 price target.
10/12/18
DBAB
10/12/18
NO CHANGE
Target $350
DBAB
Buy
Illumina price target raised to $350 from $330 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Illumina to $350 saying he sees bias to the upside for estimates over the next 6-12 months. Further, enough positive newsflow in the clinical markets should keep investors enthused about the total addressable market for nextgen sequencing, Leonard tells investors in a research note. He sees "lots of green arrows" and keeps a Buy rating on Illumina.
10/05/18
PIPR
10/05/18
NO CHANGE
Target $380
PIPR
Overweight
Illumina checks show less than expected NovaSeqs in Q3, says Piper Jaffray
Piper Jaffray analyst William Quirk says channel checks found 32 NovaSeqs placements in Q3, which suggests Illumina likely placed 60-66 in the quarter, lower than his estimate of 85 and consensus expectations of 89. The analyst, who admits being surprised "with this low check," recommends using any weakness in Illumina shares from placement weakness as a buying opportunity. A stock pullback would present an attractive entry point for a long-term position in Illumina shares "given their myriad of opportunities," Quirk tells investors in a research note. The analyst keeps an Overweight rating on the shares with a $380 price target.
FLDM Fluidigm
$7.49

-0.45 (-5.67%)

HZNP Horizon Pharma
$19.07

-0.01 (-0.05%)

09/24/18
PIPR
09/24/18
NO CHANGE
Target $25
PIPR
Overweight
Piper reiterates Overweight rating on Horizon Pharma after expert call
After hosting a call featuring an expert focused on thyroid eye disease, also known as Graves' orbitopathy, Piper Jaffray analyst David Amsellem reiterates an Overweight rating on Horizon Pharma with a $25 price target. The analyst says commentary from the expert heightened his confidence that Horizon's teprotumumab "will emerge as a paradigm-shifting option" in the broader thyroid eye disease treatment landscape. The expert views teprotumumab not only as a means of avoiding surgical intervention but also as a potential option in less severe patients who are not necessarily headed for surgery, Amsellem tells investors in a research note. He believes Horizon remains well positioned for long-term annual EBITDA growth "that is solidly in the double-digits."
10/05/18
JMPS
10/05/18
NO CHANGE
Target $22
JMPS
Outperform
Horizon's teprotumumab data 'a game-changer,' says JMP Securities
JMP Securities analyst Donald Ellis called Horizon Pharma's long-term, 72-week data on teprotumumab "a game-changer" that he believes will position the drug as a first-line therapy for treating thyroid eye disease, or TED. Ellis, who foresees a potential filing for teprotumumab in mid-2019 and potential approval in early 2020, keeps an Outperform rating and $22 price target on Horizon Pharma shares.
10/04/18
GSCO
10/04/18
NO CHANGE
Target $26
GSCO
Buy
Horizon Pharma teprotumumab data 'highly encouraging,' says Goldman Sachs
After Horizon Pharma announced 72-week durability data for its phase 2 trial of teprotumumab in treatment of thyroid eye disease, or TED, Goldman Sachs analyst Dana Flanders called the data "highly encouraging" and supportive of the drug being competitive to, and potentially better than, the current medical standard of care. The analyst, who forecasts risk-adjusted sales of greater than $200M by 2025 for teprotumumab, said those estimates are likely still conservative. Flanders reiterates a Buy rating on Horizon shares with a $26 price target.
NVTA Invitae
$12.86

-0.23 (-1.76%)

01/05/18
LTCO
01/05/18
INITIATION
Target $15
LTCO
Buy
Invitae initiated with a Buy at Ladenburg
Ladenburg initiated Invitae with a Buy and $15 price target.
NSTG NanoString
$15.18

-0.41 (-2.63%)

09/13/18
JPMS
09/13/18
NO CHANGE
Target $20
JPMS
Overweight
NanoString price target raised to $20 from $17 at JPMorgan
JPMorgan analyst Tycho Peterson raised his price target for NanoString to $20 after hosting a dinner with management. The analyst came away "impressed" at the degree of customer interest in digital spatial profiling, now branded GeoMx, ahead of commercial launch in the first half of 2019. He cites management's "bullish tone around the launch" for his target bump and keeps an Overweight rating on NanoString.
10/09/18
UBSW
10/09/18
INITIATION
Target $23
UBSW
Buy
NanoString initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated NanoString with a Buy rating and $23 price target.
QGEN Qiagen
$35.91

0.455 (1.28%)

01/22/18
LEHM
01/22/18
NO CHANGE
Target $60
LEHM
Overweight
Quidel price target raised to $60 from $50 at Barclays
Barclays analyst Jack Meehan raised his price target for Quidel (QDEL) to $60 from $50 and for Qiagen (QGEN) to $40 from $39 ahead of the companies' Q4 results. The fundamental drivers for the Life Science Tools & Diagnostics group are "on a solid footing" into earnings, Meehan tells investors in a research note. The analyst favors both names with Overweight ratings.
01/08/18
PIPR
01/08/18
NO CHANGE
PIPR
Qiagen, DiaSorin partnership could be disruptive to TB market, says Piper Jaffray
Piper Jaffray analyst William Quirk notes that Qiagen (QGEN) announced a partnership with DiaSorin to develop an automated QuantiFERONTB test for the LIAISON analyzers, and argues that it could be disruptive to the existing physician office latent TB market. The analyst believes the agreement could put pressure on some of Oxford's (OXFD) business and potentially force the company to sign a similar deal with a different immunoassay provider. Quirk points out that Oxford also announced preliminary Q4 revenue below the Street, and while the company did not explain the weak results, he believes it was from U.S. immigration weakness and China order timing.
01/03/18
EVER
01/03/18
INITIATION
Target $35
EVER
Outperform
Qiagen initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ross Muken initiated Qiagen with an Outperform rating and $35 price target.
01/29/18
GSCO
01/29/18
INITIATION
Target $39
GSCO
Buy
Qiagen initiated with a Buy at Goldman Sachs
Goldman analyst Patrick Donnelly initiated Qiagen with a Buy and $39 price target telling investors it will benefit from a wave of diagnostics product cycles which should lead to MSD-HSD organic growth as HPV headwinds abate in first half 2018.
DGX Quest Diagnostics
$102.49

0.12 (0.12%)

09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper Jaffray confident on Oxford path to profitability after Quest deal
Piper Jaffray analyst William Quirk notes that Quest Diagnostics (DGX) announced the acquisition of the U.S. laboratory services business from Oxford Immunotec (OXFD), paying $170M for about $55M in tick-borne disease and TB revenue. The deal streamlines Oxford Immunotec into essentially a kit company with better margins and an opportunity to vie for Qiagen's attractive Quest business, he contends, adding that the TB market has been growing in the mid-teens in the U.S., largely converting existing volume from the skin test to the more accurate IGRA class of assays. Long-term, Quirk believes Oxford's revenue estimates may be more predictable than they have been in the past, and his confidence in the company's path to profitability is improved following the deal announcement.
10/19/18
BOFA
10/19/18
INITIATION
Target $116
BOFA
Buy
Quest Diagnostics reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Derik de Bruin reinstated Quest Diagnostics with a Buy and $116 price target saying valuation is undemanding. de Bruin sees upside from Medicare reimbursement cuts which should result in lab consolidation, monetization of lab data, and retail clinic opportunities.
09/24/18
FBCO
09/24/18
NO CHANGE
Target $128
FBCO
Outperform
Quest Diagnostics price target raised to $128 from $121 at Credit Suisse
Credit Suisse analyst A.J. Rice raised his price target for Quest Diagnostics to $128 from $121 after meeting with CEO Steve Rusckowski and VP of Investor Relations Shawn Bevec. The analyst notes that management sees the clinical lab industry going through a period of disruptive change that should play to the strengths of national laboratory companies, such as Quest, at the expense of small regional labs and hospital outreach programs. Rice reiterates an Outperform rating on the shares.
09/25/18
PIPR
09/25/18
NO CHANGE
PIPR
Piper sees early winners from annual list of new codes from CMS
The Centers for Medicare & Medicaid Services published its annual list of new codes ahead of the final rate determination including 99 codes, Piper Jaffray analyst William Quirk tells investors in a research note. He says Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA) and Quest Diagnostics (DGX) look like early winners in the 2019 Preliminary Clinical Laboratory Fee Schedule Fee Schedule determinations, with an incrementally positive competitive move for CareDx (CDNA). The analyst notes that Genomic Health received increased reimbursement for a couple tests and CareDx competitor TAI Diagnostics ends up with a likely longer pathway to reimbursement.
RTRX Retrophin
$25.34

0.24 (0.96%)

04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.
TMO Thermo Fisher
$227.13

-2.51 (-1.09%)

10/09/18
UBSW
10/09/18
INITIATION
Target $295
UBSW
Buy
Thermo Fisher initiated with a Buy at UBS
UBS analyst Daniel Brennan initiated Thermo Fisher with a Buy rating and $295 price target.
10/18/18
CLVD
10/18/18
DOWNGRADE
CLVD
Neutral
Thermo Fisher downgraded to Neutral from Buy at Cleveland Research
10/18/18
10/18/18
DOWNGRADE

Neutral
Follow-up: Thermo Fisher downgraded to Neutral at Cleveland Research
As previously reported, Cleveland Research downgraded Thermo Fisher to Neutral from Buy. Analyst Steve Willoughby said feedback indicates "extremely strong trends" in the industry are "unlikely to be sustained" at the same rate going into 2019. The analyst is now assuming softer than expected organic growth, less contribution from M&A, and FX headwinds. Willoughby is now slightly below consensus with his estimates and sees less upside in shares going forward.
WTKWY Wolters Kluwer
$0.00

(0.00%)

ARQL ArQule
$4.33

-0.38 (-8.07%)

06/12/18
06/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. InterDigital (IDCC) initiated with a Buy at Roth Capital. 2. Weight Watchers (WTW) initiated with an Overweight at JPMorgan and a Buy at DA Davidson. 3. Franklin Electric (FELE) initiated with a Neutral at DA Davidson. 4. ArQule (ARQL) initiated with an Outperform at Oppenheimer. 5. comScore (SCOR) initiated with a Buy at Loop Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/29/18
RILY
06/29/18
NO CHANGE
Target $7.5
RILY
Buy
ArQule price target raised to $7.50 from $4.00 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $7.50 saying the positive clinical results with BTK and AKT inhibitors, along with the Basilea Pharma deal, add to his confidence. The analyst keeps a Buy rating on the shares.
06/11/18
OPCO
06/11/18
INITIATION
Target $7
OPCO
Outperform
ArQule initiated with an Outperform at Oppenheimer
Oppenheimer initiated ArQule with an Outperform and $7 price target.
04/17/18
ROTH
04/17/18
NO CHANGE
Target $6
ROTH
Buy
ArQule price target raised to $6 after AACR meeting at Roth Capital
Roth Capital analyst Jotin Marango noted that ArQule presented clinical data on its BTK inhibitor ARQ 531 and its AKT inhibitors Miransertib and ARQ 751 at the AACR meeting this weekend and subsequently reported the outlicensing of its FGFR inhibitor derazantinib. He believes that over the last few days the company has been able monetize its "riskier and costlier program" while presenting data that build material value into its rising programs, Marango tells investors. He raised his price target on ArQule shares to $6 from $5 and keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

AAPL

Apple

$193.42

2 (1.04%)

, PCG

PG&E

$24.39

6.62 (37.25%)

19:29
11/18/18
11/18
19:29
11/18/18
19:29
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

AAPL

Apple

$193.42

2 (1.04%)

PCG

PG&E

$24.39

6.62 (37.25%)

CBS

CBS

$57.49

0.23 (0.40%)

VIA

Viacom

$37.05

0.96 (2.66%)

VIAB

Viacom

$33.00

1.13 (3.55%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

TGT

Target

$79.67

-1.09 (-1.35%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TIF

Tiffany

$106.48

0.52 (0.49%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TJX

TJX

$51.47

-0.98 (-1.87%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

LB

L Brands

$35.28

-0.41 (-1.15%)

T

AT&T

$30.30

0.18 (0.60%)

BP

BP

$40.85

-0.3 (-0.73%)

CVX

Chevron

$119.14

2.18 (1.86%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

APC

Anadarko

$56.39

0.9 (1.62%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

AMGN

Amgen

$194.23

1.83 (0.95%)

THS

TreeHouse

$51.92

0.72 (1.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 26

    Nov

  • 27

    Nov

  • 28

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 18

    Jan

  • 22

    Jan

  • 03

    Mar

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

, BX

Blackstone

$32.48

-0.02 (-0.06%)

18:50
11/18/18
11/18
18:50
11/18/18
18:50
Periodicals
Zayo said to get interest from Blackstone-Stonepeak Group, Bloomberg reports »

Zayo (ZAYO) has attracted…

ZAYO

Zayo Group

$23.70

1.495 (6.73%)

BX

Blackstone

$32.48

-0.02 (-0.06%)

KKR

KKR

$21.83

-0.46 (-2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 03

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:08
11/18/18
11/18
18:08
11/18/18
18:08
Periodicals
PG&E reports another outage on morning when California started, Reuters says »

PG&E, facing investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KL

Kirkland Lake Gold

$18.97

0.28 (1.50%)

18:04
11/18/18
11/18
18:04
11/18/18
18:04
Hot Stocks
Kirkland Lake Gold appoints David Soares as CFO, Eric Kallio as senior VP »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPD

Expeditors

$73.67

0.14 (0.19%)

17:19
11/18/18
11/18
17:19
11/18/18
17:19
Conference/Events
Expeditors management to meet with Wolfe Research »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CBS

CBS

$57.49

0.23 (0.40%)

, VIAB

Viacom

$33.00

1.13 (3.55%)

16:54
11/18/18
11/18
16:54
11/18/18
16:54
Periodicals
CBS, Viacom merger could be a few months away, NY Post reports »

After CBS (CBS) CEO Les…

CBS

CBS

$57.49

0.23 (0.40%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 04

    Dec

AIMT

Aimmune

$29.61

0.05 (0.17%)

16:51
11/18/18
11/18
16:51
11/18/18
16:51
Hot Stocks
PALISADE trial of Aimmune's AR101 published in New England Journal of Medicine »

Aimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 12

    Dec

T

AT&T

$30.30

0.18 (0.60%)

, CMCSA

Comcast

$38.60

0.11 (0.29%)

16:31
11/18/18
11/18
16:31
11/18/18
16:31
Hot Stocks
Box Office Battle: 'Fantastic Beasts 2' wins weekend with $62M »

AT&T (T) subsidiary…

T

AT&T

$30.30

0.18 (0.60%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$50.80

-0.81 (-1.57%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

LGF.A

Lionsgate

$20.88

0.365 (1.78%)

DIS

Disney

$116.20

-0.9 (-0.77%)

VIAB

Viacom

$33.00

1.13 (3.55%)

VIA

Viacom

$37.05

0.96 (2.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

VLKAY

Volkswagen

$0.00

(0.00%)

, GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

15:45
11/18/18
11/18
15:45
11/18/18
15:45
Periodicals
Volkswagen CEO says Waymo has 1/2-year head start, Reuters reports »

Volkwagen (VLKAY) is up…

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

15:21
11/18/18
11/18
15:21
11/18/18
15:21
Hot Stocks
AT&T, Fox Networks renew multi-year deal across distribution platforms »

AT&T (T) and Fox…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

AAPL

Apple

$193.42

2 (1.04%)

13:35
11/18/18
11/18
13:35
11/18/18
13:35
Periodicals
Apple CEO views new regulations as 'inevitable,' Axios reports »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, RIO

Rio Tinto

$50.94

0.89 (1.78%)

13:05
11/18/18
11/18
13:05
11/18/18
13:05
Periodicals
Nespresso, Rio Tinto joining forces to make coffee pods greener, Reuters says »

Nespresso, part of food…

NSRGY

Nestle

$0.00

(0.00%)

RIO

Rio Tinto

$50.94

0.89 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$1.11

-0.095 (-7.92%)

12:54
11/18/18
11/18
12:54
11/18/18
12:54
Hot Stocks
Sonoma Pharmaceuticals announces pricing of public offering of units »

Sonoma Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 04

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/18/18
11/18
04:55
11/18/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.